TLR4 and neoplasm: CircGFRA1 knockdown can inhibit the resistance of TNBC cells to PTX by reducing the expression of TLR4, which has been found to be activated by paclitaxel to improve tumor cell survival and blocking TLR4 could significantly improve response to paclitaxel therapy in BC [50, 93].